Frankfurt At the biotech company Curevac, another change in leadership is apparently in the offing. According to information from the Handelsblatt from the industry, the Tübingen-based company, which failed last year with the development of a Covid vaccine, is now intensively on the lookout for a new CEO who is to succeed the previous company boss Franz-Werner Haas in the coming year.
Haas’ contract was extended by another year until mid-2023 at the most recent annual general meeting. The company itself does not provide any information on further planning of the board positions, as does the main shareholder, Dievini Hopp Biotech Holding, in which SAP founder Dietmar Hopp has bundled his biotech commitments.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue